I spoke to Todd. He was extremely generous with hi

I spoke to Todd. He was extremely generous with his time. I will not quote him.

I did not think to ask him about the transcript as Joe already said why it had not been posted.

The folks at Generex are as frustrated as we are about BARDA and the SEC. Having said that the research we are doing on CV-19 etc as well as the recent breast cancer 10 year data is exciting and should lead to higher valuations as we garner interest from investors/partners etc.

The info that has been made public is up to date.

Perhaps GNBT's recent reorganization has slowed down certain progress with BARDA and since the S-1 is part of that reorganization....

Perhaps Generex's plan to spin off NGIO and distribute dividends has slowed down the SEC as they nitpick every little thing. I think Joe has stated this himself.

Recent trading volume increase is interesting given all the things GNBT/NGIO has announced.

Progress continues in spite of difficulties with financing and Generex is committed to obtaining quality funding vs working with the loan sharks.



I suggest everyone email and call the SEC about the GNBT S-1.